Month: 2026-03

EQS Newswire / 27/03/2026 / 23:12 UTC+8 【For Immediate release】 Trio Industrial Electronics Group Limited (Stock Code: 1710.HK) Announces 2025 Annual Results* * * Recorded Revenue at approximately HK$775.3 million Continues to implement Dual‑engine Strategy of Electronic Manufacturing Services and New Energy Businesses to Build a “Greater Asia New Energy Business Network” (Hong Kong – 27 March 2026) Trio Industrial Electronics Group Limited (“Trio Industrial” or the “Group”; stock code: 1710), a leading manufacturer and distributor of advanced industrial electronic components and products in Hong Kong, today announced the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2025 (the “Year”). During the Year, the overall operating environment remained challenging. Europe and North America continued to be the Group’s major markets, where operating conditions were affected by relatively tight interest rate conditions, ongoing geopolitical tensions and the implementation of the revised tariff policy in the United States. In response, many customers adopted a more prudent procurement approach, focusing on inventory management and adjusting their purchasing strategies, which led to weaker demand during the Year. As a result, the Group’s revenue for the financial year 2025 decreased by approximately 23.1% year‑on‑year to approximately HK$775.3 million. Nevertheless, the Group maintained stringent cost control and optimised its staffing and labour structure, resulting in a decrease in overall administrative expenses compared with last year. Overall, the Group recorded a gross profit of approximately HK$139.6 million for the financial year 2025, representing a decrease of approximately 25.5% compared with the previous year, while gross profit margin decreased by 0.6 percentage points from 18.6% to 18.0%. The Group recorded a loss attributable to owners of the Company of approximately HK$35.4 million for the Year. The Group maintained a healthy financial position, with cash and cash equivalents (including restricted bank deposits) of approximately HK$140.5 million and a net cash position (cash and cash equivalents less borrowings). The current ratio was approximately 2.7 times, similar to that as at 30 June 2025 and 31 December 2024. To navigate the complex and evolving global market environment, Trio Industrial is accelerating the implementation of its joint design manufacturing strategy, deepening cooperation with key customers and enhancing value‑add and profit potential from the product design stage, while strengthening long‑term customer relationships. In line with this direction, the Group is actively recruiting professionals who possess both technical expertise and market insights to enhance its global sales and engineering teams, further expand market coverage and support future business growth. In terms of global manufacturing network, the Group’s Thailand production facility serves as a strategic export base for the United States of America and Southeast Asian markets, providing greater flexibility in addressing geopolitical developments and tariff barriers. The Group’s manufacturing facility in the United Kingdom commenced operation in the second quarter of 2025 to serve local customers in Europe and strengthen supply chain security. The Group is also establishing a new manufacturing facility in the United States of America, which is expected to commence operation in the second half of 2026. With a manufacturing network spanning the PRC, Thailand, the United Kingdom and the upcoming facility in the United States of America, the Group is able to offer global customers diversified regional supply assurance and flexibility in response to geopolitical changes and the reshaping of trade patterns. This network not only enhances supply chain resilience, but also underscores the Group’s competitive advantage of “global manufacturing, local services”. In the new energy sector, while optimising the operations of its electronic manufacturing services business, the Group has continued to expand its business from electric vehicle charging manufacturing and charging station operation to include energy storage and distributed energy applications, thereby building an integrated “charging–storage–energy services” business model and further consolidating its position along the new energy value chain. Leveraging the “Belt and Road” Initiative, the Group has established first‑mover platforms in Central Asia and Southeast Asia and is advancing distributed energy storage and e‑mobility projects with regional demonstration effects, injecting new momentum into its medium‑ to long‑term growth. In Kazakhstan, the Group has partnered with Sinooil (a subsidiary of China National Petroleum Corporation) to deploy electric vehicle charging infrastructure and digital advertising facilities at approximately 140 Sinooil petrol stations across the country, creating a scalable platform for the Group’s integrated energy and media business. The Group has established four EV charging stations in Kazakhstan, one of which adopts a “solar‑storage‑charging” configuration, integrating Deltrix EV charging infrastructure, energy storage systems, digital advertising kiosks and intelligent car‑wash facilities. While providing EV charging services, these sites also create a comprehensive ecosystem that combines energy services, digital advertising, automatic car‑wash facilities and convenience retail. This integrated advertising platform is also designed to support Chinese enterprises in expanding into Central Asia and to strengthen the Group’s presence in the regional outdoor media market. Building on this strategic platform in Central Asia, the Group is also expanding its new energy business in Southeast Asia, with the Philippines as the first market in the region. The Group is rolling out Deltrix‑branded electric motorcycles and battery‑swapping projects, offering an integrated “vehicle–battery–cabinet” solution for e‑mobility, which is a typical distributed energy storage application. At the same time, the Group is developing other distributed energy storage solutions for residential, commercial and industrial applications, further broadening its portfolio of new energy products and services in the region. Mr. Cecil Wong, the Chairman of Trio Industrial Electronics Group Limited said, “Despite the continued challenges in the global economic environment, we remain confident in the long‑term trends of industrial electrification, sustainable energy and intelligent development. The Group’s strength lies in combining its expertise in electronic manufacturing with new energy technologies, and in driving business development through a multi‑country manufacturing footprint and technology‑driven execution. Over the next three years, we will focus on business areas with sustainable growth potential, strong technology orientation and clear market demand to further enhance the Group’s earnings quality and cash flow performance.” “At the same time, we will promote deeper integration of artificial intelligence and the Internet of Things to build the ‘Group Intelligent Energy Brain’, using data to drive operational efficiency and transparency in energy management, and ultimately achieve the transformation from a manufacturing enterprise into an intelligent energy ecosystem platform. We believe that by continuously optimising operational efficiency and advancing the integrated development of ‘new energy + new media’, Trio Industrial will further strengthen its competitive advantages amid a rapidly changing market environment, open up high value‑added and sustainable growth opportunities and create long‑term value for shareholders.” - End - About Trio Industrial Electronics Group Limited (Stock Code: 1710.HK) Trio Group is a leading Hong Kong-based manufacturer and supplier of advanced industrial electronic components and products, with over 40 years of industry expertise. Specialising in power supply solutions, the group serves key sectors such as energy efficiency and medical electronics. As the first Hong Kong electronics supplier to achieve Industry 4.0 maturity certificate - industry 4.0 1i level. Trio Group integrates smart manufacturing and innovative technologies to deliver high-performance solutions, earning a strong reputation as a trusted partner for numerous globally recognised brands, primarily in Europe and North America. In response to the growing emphasis on ESG (Environmental, Social, and Governance) principles and the urgent demand for decarbonisation, Trio Group is strategically expanding into the renewable energy sector through its proprietary brand, Deltrix. The company is actively developing solutions in: EV charging infrastructure Solar energy storage systems Smart power management Charging network deployment With a focus on Central Asia and Southeast Asia, Trio Group is committed to advancing green technology innovation, positioning itself as a key player in the global energy transition while driving sustainable business growth. By leveraging its technical expertise and forward-looking strategies, the group continues to reinforce its role in shaping a low-carbon future. This press release is issued by DLK Advisory Limited on behalf of Trio Industrial Electronics Group Limited. For further information, please contact: DLK Advisory 金通策略 Email: pr@dlkadvisory.com Tel: +852 2857 7101 File: 1710_2025AR_press release_EN_20260327_FINAL 27/03/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS 新聞 / 2026-03-27 / 23:12 UTC+8 [請即時發布] 致豐工業電子集團有限公司 （股份代號：1710.HK） 公佈2025年全年業績 * * * 收益約為7.753億港元 持續推行電子製造服務及新能源業務雙引擎發展策略 建立「大亞洲新能源業務圈」 (香港 – 2026年 3月 27日) 香港領先的工業電子零件及產品製造及銷售企業 – 致豐工業電子集團有限公司（「致豐集團」或「集團」，股份代號：1710），今日宣佈本公司及其子公司（「本集團」）截至2025年12月31日止年度（「年內」）的全年業績。 年內，整體經營環境仍然充滿挑戰。歐洲及北美仍為本集團的主要市場，而當地的經營環境受到相對緊縮的利率環境、持續的地緣政治緊張局勢以及美國修訂關稅政策實施等因素所影響，不少客戶採取更審慎的採購方法，著重庫存管理並調整採購策略，導致年內需求轉趨疲弱。因此，本集團於2025財政年度的收入較去年下降約23.1%至約為7.753億港元。然而，本集團仍維持嚴格的成本控制，並優化其人員及勞動結構，使整體行政開支較去年有所下降。整體而言，本集團於2025財政年度錄得毛利約1.396億港元，較去年同期減少約25.5%，毛利率由去年的18.6%減少0.6個百分點至18.0%。本集團年內錄得本公司擁有人應佔虧損35.4百萬港元。集團保持穩健的財務狀況，現金及現金等價物（包括受限制銀行存款）約為1.405億港元，維持正淨現金狀況（現金及現金等價物減借款）。流動比率約為 2.7倍，與於2025年6月30日及2024年12月31日相若。 為應對複雜多變的全球市場環境，致豐集團正加速推進聯合設計製造策略，深化與主要客戶的合作，從產品設計端着手提升附加價值與利潤潛力，同時鞏固長期客戶關係。配合此方向，本集團積極引入兼具技術背景與市場洞察力的專業人才，優化全球銷售與工程團隊，進一步拓展市場覆蓋並支持未來業務增長。在全球製造布局方面，泰國生產設施作為出口至美國及東南亞市場的策略性出口基地，為本集團在應對地緣政治發展及關稅壁壘方面提供更大的靈活性。本集團位於英國的製造設施已於2025年第二季度投入運作，為歐洲本地客戶提供服務並加強供應鏈安全。本集團亦正於美國建立新的製造設施，預期將於2026年下半年投入運作。致豐集團已建立覆蓋中國、泰國、英國及即將在美國投產的製造網絡，為全球客戶提供多區域供應保障與彈性，以應對地緣政治變化及貿易格局重塑。該布局不僅增強供應鏈韌性，亦體現本集團「全球製造、本地服務」的競爭優勢。 於新能源領域，在優化電子製造服務業務運營的同時，本集團業務持續拓展，從電動汽車充電與充電設施運營延伸至能源儲存與分佈式能源應用，構建「充電－儲能－能源服務」一體化業務模式，進一步鞏固其於新能源價值鏈的地位。配合「一帶一路」倡議，本集團已於中亞及東南亞市場建立先行平台，並正在推進具區域示範效應的分佈式儲能及電動出行項目，為中長期增長注入新動能。在哈薩克斯坦，本集團已與Sinooil（中國石油天然氣集團）合作，在全國約140個Sinooil加油站部署電動汽車充電基礎設施及數字廣告設施，為本集團能源與媒體綜合業務建立可擴展的平台。本集團已於哈薩克斯坦建立四個電動汽車充電站，其中一個採用「光儲充」配置，整合Deltrix電動汽車充電基礎設施、能源儲存系統、數字廣告亭及智能洗車設施。該等站點在提供電動汽車充電服務的同時，亦構建了一個結合能源服務、數字廣告、自動洗車設施及便利零售的綜合生態系統。該綜合廣告平台亦旨在協助中國企業進軍中亞，同時加強本集團於區域戶外媒體市場的定位。 在中亞建立此策略平台的基礎上，本集團亦正拓展其於東南亞的新能源業務，其中菲律賓為區域擴展的首個市場。本集團正推進Deltrix品牌電動摩托車及換電項目，為電動出行提供「車－ 電－ 櫃」一體化解決方案。這是典型的分佈式儲能應用解決方案。同時，本集團亦正開發適用於住宅及工商業用途的其他分佈式儲能解決方案，進一步擴展其於該地區的新能源產品及服務組合。 致豐工業電子集團主席黃思齊先生表示：「儘管環球經濟環境仍存挑戰，我們依然堅信產業電氣化、能源可持續化及智能化發展的長期趨勢不變。致豐集團的優勢在於結合電子製造專業與新能源技術，並以多國製造佈局與技術驅動的策略執行力，推動業務持續發展。展望未來三年，我們將聚焦具可持續增長潛力、技術導向及市場需求明確的業務範疇，進一步提升集團的盈利質量與現金流表現。同時，我們將推動人工智能與物聯網的深度融合，構建『集團智能能源大腦』，以數據驅動營運效率與能源管理透明化，最終實現從製造型企業向智能能源生態平台的轉型。我們相信，通過持續優化營運效率及推進「新能源 + 新媒體」的融合發展，致豐集團將在不斷變化的市場環境中鞏固競爭優勢，開拓高附加值、可持續的增長空間，為股東創造長期價值。」 - 完 – 關於致豐工業電子集團有限公司（股份代號：1710.HK） 致豐集團是香港領先的工業電子零件及產品製造商，擁有超過40年的行業經驗，專注於高品質電源產品的生產與銷售，業務涵蓋節能、醫療等關鍵領域。作為香港電子工業供應商中首家榮獲工業4.0成熟度1i級認證的企業，集團以智能化製造與創新技術為核心，為全球客戶提供高效可靠的解決方案，並成為眾多國際知名品牌的長期合作夥伴，客戶群主要遍及歐美市場。 面對全球ESG（環境、社會與治理）趨勢與零碳轉型需求，致豐集團積極佈局可持續能源領域，透過旗下自主品牌Deltrix拓展可再生能源、儲能技術及綠色基礎設施業務。市場版圖延伸至中亞與東南亞，服務範疇包括： 電動車充電解決方案 光伏儲能系統 智能電源管理系統 充電網絡基礎設施 憑藉深厚的技術積累與前瞻性的產業佈局，致豐集團持續推動綠色科技創新，致力成為全球能源轉型中的關鍵參與者，實踐企業永續發展願景。 此新聞稿由金通策略有限公司代致豐工業電子集團有限公司發布。 如有任何查詢，請聯絡： DLK Advisory 金通策略 電郵: pr@dlkadvisory.com 電話: +852 2857 7101 文件: 1710_2025AR_press release_TC_20260327_FINAL 2026-03-27 此財經新聞稿由EQS Group轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS Newswire / 27/03/2026 / 21:31 UTC+8 Record-Breaking Revenue of HK$586.2M and EPS Surged to HK$1.56 Cents Dividends Distributed for Two Consecutive Years Embarks on Innovation-Driven Transformation to Become a Global Pioneer in Regenerative Medicine (27 March 2026 – Hong Kong) A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”). Key Accomplishments in 2025 During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include: During the Year, the Group delivered record-breaking financial results, with revenue recorded a 6.0% year-on-year (“YoY”) increase, reaching approximately HK$586.2 million. Profit for the year soared by 12.7% YoY to approximately HK$93.3 million, and net profit margin increased by 1.0 percentage points YoY to 15.9%, marking a historic high. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025. The Group generated solid cash from operations in the Year, operating cash flow and free cash flow increased by 32.7% and 27.3% YoY, respectively. Cash ratio increased from 0.53 times at the end of 2024 to 1.63 times at the end of 2025. The cash conversion cycle improved from 124 days to 107 days, highlighting greater operating efficiency. Backed by sustainable earnings and a healthy cash flow, the board of directors (“Board”) has declared a dividend payment for 2025 of HK$0.313 cents per share. Since its official launch in March 2024, Bogutai® has sustained strong growth momentum, driven by a solid commercialization strategy and successful academic engagement. In 2025, Bogutai® demonstrated rapid market adoption in China, achieving a remarkable year-on-year revenue growth of 111.0%. In May 2025, the Group’s second ophthalmology product, 金因康® (Diquafosol Sodium Eye Drops), received marketing approval from the China National Medical Products Administration (“NMPA”), marking a significant milestone in expanding the Group’s ophthalmic portfolio following GeneSoft®. The Group is actively preparing its launch and marketing strategy. In addition to leveraging synergy with GeneSoft® and its established online and offline distribution network for rapid market penetration, 金因康® will specifically target the mid-to-high-end segment of dry eye patients outside the hospital setting, those who prioritize long-term efficacy and premium product quality. In June 2025, the Group officially launched the high-end series GeneQueens® of 肌顏態® and the medical device brand 金因敷®, marking two key milestones in its strategic expansion into the integrated“Drug, Medical Device, and Aesthetics”field. These product launches reflect the Group’s commitment to enhancing its skin health product matrix and addressing evolving consumer needs for efficacy-driven, medical-grade skincare in both functional skincare and post-aesthetic recovery. In July 2025, the marketing application of Isavuconazonium sulfate capsules were officially accepted by the NMPA. Isavuconazonium sulfate capsules are expected to be approved for launch as early as the fourth quarter of 2026, offering a safer, more effective, and high-quality treatment option for patients suffering from invasive fungal infections. In 2025, the Group established a strategic partnership with Wenzhou Medical University to explore a thermosensitive gel formulation combining EGF and bFGF, leveraging the university’s proven expertise in bFGF production. As a key growth factor in regenerative medicine, bFGF is highly effective in promoting granulation and angiogenesis. Towards the end of 2025, the Group repositioned its long-term strategy from “Stable Growth” to “Innovation-Driven,” signifying a bold transformation from an integrated pharmaceutical company into a global pioneer in regenerative medicine. The Group is advancing a transformative R&D strategy spanning four key areas: muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration. Annual Results For 2025, the Group recorded a revenue of approximately HK$586.2 million, representing an increase of 6.0% YoY. Revenue from Bogutai® increased from approximately HK$ $63.5 million to approximately HK$ 134.0 million, representing a significant increase of 111.0%. Revenue generated from GeneTime® was approximately HK$220.4 million, representing an increase of 10.9% YoY. GeneSoft® recorded a 7.9% YoY decrease in revenue from approximately HK$41.9 million to approximately HK$38.6 million due to intense market competition. Pinup® recorded a decrease of 29.4% in revenue from approximately HK$244.2 million to approximately HK$172.5 million for the Year. In 2025, the Group adopted a more disciplined and selective hospital-supply strategy under volume-based procurement (VBP) to safeguard margins, particularly in regions where policy adjustments intensified price competition. At the same time, the Group accelerated diversification into pharmacy networks beyond traditional hospital channels and optimized its supply chain to improve cost and profitability. In 2024, Boshutai® was successfully included in the VBP by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years. Hospitals in many provinces began procuring Boshutai® in 2025. Following the destocking and a low base in 2024, revenue from Boshutai® increased from approximately HK$10.2 million to approximately HK$15.5 million, representing a significant increase of 51.9%. 肌顏態® generated approximately HK$2.8 million in revenue in its early stage. The limited revenue scale reflected several factors, including a relatively small number of products approved and launched during the Year, and the fact that specialized marketing and distribution teams were still being built and optimized. Gross profit was approximately HK$487.6 million, representing an increase of 5.7% as compared with approximately HK$461.1 million in 2024, and gross profit margin increased by 0.2 percentage points YoY to 83.2%. The Group delivered another year of record-breaking profit, achieving approximately HK$93.3 million for the Year, representing an increase of 12.7% YoY. Net profit margin increased by 1.0 percentage points YoY to 15.9%. These results demonstrate the Group’s success in converting product innovation into market value through strong commercialization execution and financial discipline. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY. Prospects Regenerative medicine has emerged as a rapidly developing field, focused on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. The sector has the potential to treat and address the underlying causes of chronic and advanced diseases. The global regenerative medicine market was approximately USD51.7 billion in 2025. It is projected to grow from USD63.0 billion in 2026 to USD555.6 billion by 2034, representing a compound annual growth rate (CAGR) of 31.3%. The increasing prevalence of chronic and hereditary diseases, together with rising healthcare expenditure in both developed and emerging markets, is expected to support continued growth in the regenerative medicine industry. Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “In 2025, we are proud to have delivered another year of record profitability, marking a significant milestone in our growth journey. During the year, we entered a new phase of strategic development. In anticipation of an increasingly favorable market environment, we advanced our strategic transition from ‘stable growth’ to ‘innovation-driven’ development, with a clear focus on four diversified therapeutic areas: musculoskeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration. With multiple products progressing through our pipeline and accelerating toward commercialization, the Group has continued to broaden its marketing channels. In addition to strengthening our established offline hospital networks, deepening partnerships with local distributors, and hosting academic conferences, we have actively expanded into online e-commerce platforms to enhance product accessibility and extend our market reach. Our ambitions extend well beyond China. During the year, we formed a strategic partnership with Kexing Biopharm to accelerate the global expansion of Bogutai®. Through this collaboration, we have granted Kexing Biopharm exclusive commercialization rights for Bogutai® in six international markets—Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico—laying a solid foundation for global growth. We expect these markets to begin contributing revenue as early as the end of 2026. At the same time, we are advancing the FDA approval process for Bogutai® in the United States, aiming for approval as early as 2027. In December, we also entered into a strategic collaboration with Wenzhou Medical University and the People’s Government of Ouhai District, Wenzhou, to foster a synergistic ‘government–university–enterprise’ model, further strengthening our capabilities in regenerative medicine. Supported by strong partnerships with local governments and leading academic institutions, we are well positioned to build a world-class biomedical ecosystem and enhance our end-to-end innovation capabilities.” About Uni-Bio Science Group Limited Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001 (Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to be the global leader in regenerative medicine, redefining how science restores and extends human life. For further information, please contact: ir@uni-bioscience.com 27/03/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS 新聞 / 2026-03-27 / 21:31 UTC+8 收入創新高達586.2百萬港元 每股盈利提升至1.56港仙 並連續兩年派發股息 開啟創新驅動轉型 致力于成為全球再生醫學先驅 [二零二六年三月二十七日 – 香港] 綜合性生物製藥公司 — 聯康生物科技集團有限公司（「聯康集團」或「本公司」，連同其附屬公司統稱「本集團」，股份代號：0690）欣然宣佈本集團截至二零二五年十二月三十一止年度(「年內」）的全年業績。 二零二五年取得之重大成就 年內，本集團取得了一系列成就，在已上市產品及創新的生物製劑方面均取得良好成績。主要取得的成就如下: 年內，本集團錄得破紀錄的財務業績，收入按年增長6. 0%，達到約586. 2百萬港元。溢利按年升12.7%至約93.3百萬港元，而純利率按年增加1. 0個百分點至15.9%，創歷史新高。每股盈利達到約1. 56港仙，按年增長15.5%，二零二三年至二零二五年的复合年增长率为18.55%。 本集團於年內錄得穩健的經營現金流，經營現金流量及自由現金流量分別按年增加32.7%及27.3%。現金比率由二零二四年底的0.53倍上升至二零二五年底的1.63倍。現金轉換週期從124天改善為107天，突顯營運效率顯著提升。憑藉可持續盈利及穩健的現金流，董事會建議派發末期股息每股0.313港仙。 自博固泰®於二零二四年三月正式推出以來，在穩健的商業化策略及成功的學術推廣驅動下，其保持了強勁的增長勢頭。於二零二五年，博固泰®在中國展現出快速的市場滲透率，年收入增長實現111.0%的顯著增長。 於二零二五年五月，本集團第二款眼部產品金因康®（地誇磷索鈉滴眼液）獲中國國家藥品監督管理局(NMPA)的上市批准，標誌著繼金因舒®後，本集團眼部產品線拓展之重要里程碑。本集團正積極籌備其推出及營銷策略。除利用與金因舒®及其成熟的線上及線下分銷網絡的協同效應以實現快速市場滲透外，金因康®將專門針對醫院場景以外的中高端乾眼症患者群體，即該等優先考慮長期療效及優質產品品質的患者。 於二零二五年六月，本集團正式推出肌顏態®高端系列GeneQueens®及醫療器械品牌金因敷®，此舉標誌其進軍「藥品、醫械及醫美」整合領域之兩個關鍵里程碑。該等產品發布反映本集團致力於完善其皮膚健康產品矩陣，並滿足消費者對功能性護膚及醫美術後修復領域中以功效為導向的醫學級護膚品不斷演變的需求。 於二零二五年七月，硫酸艾沙康唑膠囊的上市申請已獲國家藥品監督管理局正式受理。硫酸艾沙康唑膠囊預計最早將於二零二六年第四季度獲准上市，為侵入性真菌感染患者提供更安全、更有效且高品質的治療選擇。 於二零二五年，本集團與溫州醫科大學建立戰略合作夥伴關係，利用該大學在bFGF生產方面經證實的專業知識，共同研發結合EGF及bFGF的熱敏凝膠製劑。作為再生醫學的關鍵生長因子，bFGF在促進肉芽組織增生及血管生成方面具有高度療效。 於二零二五年底，本集團將其長期戰略由「穩健增長」重新定位為「創新驅動」，標誌著其由一家綜合製藥公司大膽轉型為全球再生醫學先驅。本集團正推進具變革性的研發戰略方向，涵蓋四大關鍵領域：肌肉骨骼再生、皮膚再生、眼部再生及耳鼻喉科再生。 全年業績 於二零二五年，本集團錄得收益約586. 2百萬港元，按年增長6. 0%。博固泰®的收益由約63.5百萬港元大幅增加至約134.0百萬港元，大幅增加111.0%。金因肽®的收益約為220.4百萬港元，按年增長10.9%。由於市場競爭激烈，金因舒®的收益由約41.9百萬港元按年減少7.9%至約38.6百萬港元。匹納普®錄得的收益由約244.2百萬港元減少29.4%至約172.5百萬港元。二零二五年，本集團在帶量採購下採取了更為嚴謹且具選擇性的醫院供應策略，以保障利潤率，特別是在政策調整加劇價格競爭的地區。同時，本集團加速向傳統醫院渠道以外的藥房網絡多元化發展，並優化其供應鏈以改善成本及盈利能力。於二零二四年，博舒泰®成功納入河南省十七省聯盟集中帶量採購，採購有效期設定為兩年。於二零二五年，許多省份的醫院開始採購博舒泰®。繼二零二四年的去庫存及較低基數之後，來自博舒泰®的收益由約10.2百萬港元增加至約15.5百萬港元，大幅增加51.9%。肌顏態®在其早期階段產生約2.8百萬港元的收益。有限的收益規模反映了幾項因素，包括於年內獲批准及推出的產品數量相對較少，以及專業營銷及分銷團隊仍處於組建及優化階段的事實。 毛利約為487.6百萬港元，較二零二四年的約461.1百萬港元增加5.7%，而毛利率按年下降0.2個百分點至83.2%。本集團實現約93.3百萬港元的破紀錄溢利，再次創下新高，按年增長12.7%。淨利潤率按年上升1.0個百分點至15.9%。該等業績證明本集團憑藉強大的商業化執行力及財務紀律，成功將產品創新轉化為市場價值。每股盈利約達1.56港仙，按年增長15.5%。 展望 再生醫學已成為一個快速發展的領域，專注於利用細胞、組織或遺傳物質修復、更換或再生受損的組織或器官。該行業具有治療及解決慢性病及晚期疾病潛在病因的潛力。全球再生醫學市場於二零二五年約為517億美元。預計將由二零二六年的630億美元增長至二零三四年的5,556億美元，複合年增長率為31.3%。慢性病及遺傳性疾病日益普遍，加上發達及新興市場的醫療保健支出不斷增加，預計將支持再生醫學行業持續增長。 聯康生物科技集團主席梁國龍先生表示：「二零二五年，我們欣然宣佈公司又實現了一年的營利突破，標誌著集團發展中重要的里程碑。年內，本集團進入策略發展的新階段。隨著市場環境逐步向好，我們積極推進由『穩定增長』轉型至『創新驅動』階段，聚焦肌肉骨骼再生、皮膚再生、眼部再生及耳鼻喉再生四大多元化治療領域。 隨著多項產品正在研發並加速邁向商業化階段，集團持續拓展多元化營銷渠道。在鞏固傳統醫療網絡、加深與本地經銷商合作以及開展學術推廣活動的同時，我們亦積極佈局線上電商平台，以進一步提升產品可及性以及擴大市場覆蓋。我們的發展戰略不限於中國市場。年內，我們與科興製藥建立了戰略合作關係，共同推動博固泰®的全球化佈局。通過此次合作，我們已授權博固泰®在沙特阿拉伯、埃及、摩洛哥、哥倫比亞、阿根廷及墨西哥六個國際市場的獨家商業化權利，為全球業務拓展奠定堅實基礎。我們預計上述市場最早將於2026年底開始貢獻收益。與此同時，我們正積極推進博固泰®在美國的FDA註冊審批。 二零二五年十二月，我們與溫州醫科大學及溫州市甌海區人民政府達成戰略合作，致力於構建『政產學研』的協同模式，進一步提升公司在再生醫學領域的能力。憑藉地方政府與頂尖學術機構的有力支持，我們有信心打造一流的生物醫藥生態體系，以提升全週期能力。」 關於聯康生物科技集團有限公司 聯康生物科技集團有限公司是一家於2001年在香港聯合交易所主板上市的創新型生物醫藥企業（股票代碼：00690.HK），致力於以下一代合成生物學技術與複雜多肽創新，驅動再生醫療發展。本集團聚焦於骨骼/肌肉再生、皮膚再生、眼部再生及耳鼻喉（ENT）再生四大核心研究領域，構建了涵蓋生物創新藥、高值仿製藥與醫療美容等板塊的多元化產品管線。本集團分別於北京、東莞及深圳均設有GMP的生產基地，具備研發、生產及商業化銷售的全鏈條能力。本集團致力於成為再生醫學領域的全球領導者，重新定義科學如何修復與延展人類生命。 如欲了解更多資訊，請聯繫： ir@uni-bioscience.com 2026-03-27 此財經新聞稿由EQS Group轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php